Alemtuzumab effective for early MS, but has serious complications
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, is an effective treatment for early multiple sclerosis, but may cause serious autoimmunity related complications, a phase II trial shows....
Want to read complete article? Please Sign in or Register.